Developing a new way to measure bone health for osteoporosis treatments
Official title: DDT-BMQ-000054: Planning for biomarker qualification, implementation and dissemination for BMD as a surrogate biomarker in future osteoporosis treatment trials: the SABRE project
Funded at University of California, San Francisco · NIH-11087988 · Data updated 2026-11-12
This study is looking at whether changes in bone density can help us find better and safer treatments for osteoporosis, so that patients can have more effective options to reduce their risk of fractures.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $250,000 |
| NIH project number | 1U01FD008422-01 |
| Project ID | NIH-11087988 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for osteoporosis or those currently undergoing treatment for the condition.
✕Less likely to help
Patients who are not at risk for osteoporosis or those who have already experienced significant fractures may not benefit from this research.
What this research studies
This research focuses on qualifying bone mineral density (BMD) as a reliable measure for evaluating new osteoporosis treatments. By analyzing data from over 150,000 patients in various trials, the project aims to establish a strong link between increases in BMD and reductions in fracture risk. The goal is to facilitate the development of safer and more effective osteoporosis medications, which could lead to more convenient treatment options for patients. The research involves collaboration with the FDA to ensure that BMD can be used as a surrogate endpoint in future clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to the development of new osteoporosis treatments that are safer and more effective, ultimately reducing the risk of fractures for patients.
How similar studies have gone: Previous research has shown promise in using BMD as a surrogate endpoint, indicating that this approach could be a significant advancement in osteoporosis treatment trials.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Black, Dennis M — University of California, San Francisco
- Study coordinator: Black, Dennis M
Related research
Other NIH-funded projects on the same topics.
-
Or olive-oil derived compound to prevent bone loss in women
A safe, orally taken nutraceutical may help prevent osteoporosis in adult women by supporting bone formation and reducing bone loss.
-
When to stop, switch, or pause long-term osteoporosis medicines for older adults
This project looks at whether stopping, switching, or taking breaks from long-term osteoporosis drugs changes fracture risk and side effects for older adults.
-
Cortical Bone Mechanics Technology to better screen for osteoporosis
A new noninvasive test called CBMT uses ulnar flexural rigidity to predict fracture risk better than standard bone density tests, helping adults who may be at risk for osteoporosis.
-
Gene therapy for osteoporosis linked to ALDH2 deficiency in postmenopausal East Asian women
A gene therapy approach is being developed to reduce osteoporosis risk in postmenopausal East Asian women who have ALDH2 deficiency and drink alcohol.
-
Metabolomics clues to osteoporosis risk in diverse populations
A study using small molecules in blood samples to understand osteoporosis risk, with a focus on aging, ethnicity, and sex differences.
-
Single-Cell Study of Bone Cells to Understand Osteoporosis
Researchers will study individual bone-related cells from people to uncover why aging leads to weaker bones and higher fracture risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.